Reata Pharmaceuticals Inc. has the cash to fund a mid-stage trial of its lead drug candidate for advanced chronic kidney disease, now that the Irving, Texas-based company has completed a $32 million Series F financing. (BioWorld Today)

As companies move ever closer to the goal of low-cost technology for sequencing the human genome, personalized medicine seems inevitable.

Poniard Pharmaceuticals Inc. is cutting 12 percent of its staff and discontinuing in-house preclinical research operations, the latest in a recent spate of layoffs. (BioWorld Today)